Compare ZNTL & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZNTL | RMM |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 276.0M |
| IPO Year | 2020 | N/A |
| Metric | ZNTL | RMM |
|---|---|---|
| Price | $1.36 | $13.64 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.87 | N/A |
| AVG Volume (30 Days) | ★ 758.1K | 66.5K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.96 |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $12.32 |
| 52 Week High | $3.33 | $16.10 |
| Indicator | ZNTL | RMM |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 31.44 |
| Support Level | $1.33 | $13.63 |
| Resistance Level | $1.46 | $13.74 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 33.33 | 4.55 |
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.